ClinicalTrials.Veeva

Menu
L

Linkoping University Hospital | Department of Neurology

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tisotumab
Icotrokinra
Platinum
Blinatumomab
Povetacicept
EVOLocumab
Osimertinib
Lazertinib
Idelalisib
Amivantamab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 13 total trials

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)

The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) a...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Pemetrexed
Drug: Carboplatin
Locations recently updated

The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately t...

Enrolling
Crohn Disease
Drug: Icotrokinra
Drug: Placebo

The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserv...

Active, not recruiting
Immunoglobulin A Nephropathy
Drug: Placebo (matched to Povetacicept)
Drug: Povetacicept

The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipi...

Active, not recruiting
Stroke
Myocardial Infarction
Drug: Evolocumab
Drug: Routine Lipid Management

The goal of this clinical trial is to learn if a new drug that might help protect and preserve kidney function in antineutrophil cytoplasmic antibody...

Enrolling
Glomerulonephritis Rapidly Progressive
Drug: Placebo
Drug: Immunosuppressive Agents

This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete...

Enrolling
Endometrial Cancer
Drug: Navtemadlin
Drug: Navtemadlin Placebo

Trial sponsors

L
Janssen (J&J Innovative Medicine) logo
A
Amgen logo
Kartos Therapeutics logo
A
N
P
S

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems